Samarth Kulkarni
Independent Chairman of BoardDr. Samarth Kulkarni also known as Sam, Ph.D, serves as the Chief Executive Officer & Chairman of the Board of CRISPR Therapeutics AG since December 1, 2017. He has been an Independent Director of Repare Therapeutics Inc. since November 2019. He serves as Trustee at The Children's Hospital Corporation since 2025. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since February 2024 and serves as its Chairman. Dr. Kulkarni served as an Independent Non-Executive Director of Centessa Pharmaceuticals plc (formerly Centessa Pharmaceuticals Limited) since February 03, 2021 until June 24, 2026. Dr. Kulkarni has been its President and Chief Business Officer since May 4, 2017 until December 1, 2017 and its Chief Business Officer since joined in August 2015 and since September 15, 2023 serves as its Chairman. He also serves as the Chairman of the Board at Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. He serves as a Director of CRISPR Therapeutics AG since June 2018. He has been an Independent Director of Black Diamond Therapeutics, Inc. since November 2019 and is its Lead Independent Director since September 2023. Dr. Kulkarni served as an Acting Principal Financial Officer of CRISPR Therapeutics AG since March 30, 2017 until November 2017 and served as its Principal Financial Officer since March 21, 2017. Dr. Kulkarni joined CRISPR Therapeutics from McKinsey and Company, where he was a Partner and had a leading role in the Pharmaceutical and Medical products practice. He joined McKinsey & Company in 2006. At McKinsey, he co-led the biotech practice and served several biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in cutting edge areas such as personalized medicine and immunotherapy, where he co-authored several publications. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, which has been published in several leading journals. Dr. Kulkarni has a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology.
Positions
- Company NameOruka Therapeutics, Inc.Stock CodeORKAPositionIndependent Chairman of BoardColleagues
- LOLawrence Otto KleinPresident, CEO & Director
- SKSamarth KulkarniIndependent Chairman of Board
- PTPaul T. QuinlanGeneral Counsel & Secretary
- JGJoana GoncalvesChief Medical Officer
- AAArjun AgarwalSenior VP of Finance & Treasurer
- LSLaura SandlerChief Operating Officer
- KMKristine M. BallIndependent Director
- PEPeter Evan HarwinIndependent Director
- ABAndrew BlauveltChairman of Scientific Advisory Board
- Company NameCRISPR Therapeutics AGStock CodeCRSPPositionCEO & ChairmanColleagues
- JRJames R. KasingerGeneral Counsel & Secretary
- RYRaju Yashaswi PrasadExecutive Officer
- NPNaimish PatelChief Medical Officer
- SFShaun FoyCo-Founder
- EMEmmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board Member
- CCCraig C. MelloScientific Founder & Advisory Board Member
- MPMatthew PorteusScientific Founder & Advisory Board Member
- DGDaniel G. AndersonScientific Founder & Advisory Board Member
- Company NameBlack Diamond Therapeutics, Inc.Stock CodeBDTXPositionLead Independent DirectorColleagues
- MAMark A. VellecaCEO, President & Chairman
- BHBrent Hatzis-SchochCOO & General Counsel
- SYSergey YurasovChief Medical Officer
- EBElizabeth BuckCo-Founder & Chief Scientific Officer
- EJErika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- ABAli BehbahaniIndependent Director
- GEGarry E. MenzelIndependent Director
- KDKapil DhingraIndependent Director
- SKSamarth KulkarniLead Independent Director
